Sumatriptan

Generic Name: Sumatriptan

Brand Names: Imitrex, Onzetra, Sumavel, Tosymra, Treximet, Zembrace

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₁N_₃O_₂S

CAS Number: 103628-46-2

Unique Ingredient Identifier: 8R78F6L9VO

Background: Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches. Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines. Sumatriptan was granted FDA approval on 28 December 1992.

Indication: A combination sumatriptan and naproxen tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and older. Sumatriptan nasal powder, nasal spray, subcutaneous injection, and tablets are indicated to treat migraines with or without auras in adults. One of the subcutaneous formulations of sumatriptan is also indicate...

Associated Conditions: Acute Migraine, Acute Cluster headaches

Associated Therapies: -

Clinical Trials

Pretreatment With Sumatriptan on Cilostazol Induced Headache in Healthy Volunteers

Not Applicable

Completed

Conditions: Migraine

Interventions: Drug: Placebo
Drug: Sumatriptan

First Posted Date: 2017-05-17

Last Posted Date: 2017-10-19

Lead Sponsor: Danish Headache Center

Target Recruit Count: 30

Registration Number: NCT03156920

Locations: 🇩🇰
Katrine Falkenberg, Copenhagen, Glostrup, Denmark

Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

Phase 1

Completed

Conditions: Migraine

Interventions: Drug: lasmiditan 200 mg
Drug: Sumatriptan
Drug: matching placebo

First Posted Date: 2017-03-10

Last Posted Date: 2019-12-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 42

Registration Number: NCT03076970

Locations: 🇺🇸
SNBL Clinical Pharmacology Unit, Baltimore, Maryland, United States

Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: Sumatriptan

First Posted Date: 2016-10-13

Last Posted Date: 2019-06-27

Lead Sponsor: Gitte Moos Knudsen

Target Recruit Count: 17

Registration Number: NCT02932488

Locations: 🇩🇰
Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark

Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Placebo
Drug: Sumatriptan
Drug: Erenumab

First Posted Date: 2016-04-18

Last Posted Date: 2019-04-02

Lead Sponsor: Amgen

Target Recruit Count: 34

Registration Number: NCT02741310

Locations: 🇧🇪
Research Site, Leuven, Belgium

The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache

Not Applicable

Completed

Conditions: Migraine

Interventions: Drug: Cilostazol
Drug: Placebo
Drug: Sumatriptan

First Posted Date: 2015-07-01

Last Posted Date: 2017-05-09

Lead Sponsor: Danish Headache Center

Target Recruit Count: 30

Registration Number: NCT02486276

Locations: 🇩🇰
Emma Katrine Hansen, Copenhagen, Glostrup, Denmark

The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache

Not Applicable

Completed

Conditions: Migraine

Interventions: Drug: 5-ISMN (isosorbide-5-mononitrate)
Drug: Placebo
Drug: Sumatriptan

First Posted Date: 2015-06-30

Last Posted Date: 2016-01-22

Lead Sponsor: Danish Headache Center

Target Recruit Count: 30

Registration Number: NCT02485340

Locations: 🇩🇰
Emma Katrine Hansen, Copenhagen, Glostrup, Denmark

Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine

Phase 4

Completed

Conditions: Migraines

Interventions: Drug: Ketorolac
Drug: Sumatriptan
Drug: Placebo

First Posted Date: 2013-03-08

Last Posted Date: 2017-03-13

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 72

Registration Number: NCT01807234

Locations: 🇺🇸
The Johns Hopkins Bayview Headache Center, Baltimore, Maryland, United States

Effect of Sumatriptan on the Postoperative Quality of Recovery After Elective Minimally Invasive Craniotomy

Not Applicable

Completed

Conditions: Postoperative Quality of Recovery
Postoperative Migrainous Headache

Interventions: Drug: Sumatriptan
Other: Placebo

First Posted Date: 2012-07-03

Last Posted Date: 2022-12-22

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 40

Registration Number: NCT01632657

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects

Phase 1

Completed

Conditions: Migraine

Interventions: Drug: Sumatriptan

First Posted Date: 2012-01-11

Last Posted Date: 2012-02-29

Lead Sponsor: Optinose US Inc.

Target Recruit Count: 20

Registration Number: NCT01507610

Locations: 🇺🇸
Celerion, Neptune, New Jersey, United States

Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

Phase 3

Completed

Conditions: Migraine Headache

Interventions: Drug: Placebo
Drug: Sumatriptan

First Posted Date: 2011-10-31

Last Posted Date: 2015-05-06

Lead Sponsor: Optinose US Inc.

Target Recruit Count: 223

Registration Number: NCT01462812

Locations: 🇺🇸
Premiere Research Institute, West Palm Beach, Florida, United States
🇺🇸
Headache Wellnes Center, Greensboro, North Carolina, United States
🇺🇸
MedVadis, Watertown, Massachusetts, United States

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy